Ironwood Pharmaceuticals

What Ironwood Pharmaceuticals does

Ironwood Pharmaceuticals is a Boston, Massachusetts-based, publicly traded (NASDAQ: IRWD) gastrointestinal-focused biopharmaceutical company founded in 1998 that develops and commercializes prescription treatments for GI diseases. Its commercial product is LINZESS (linaclotide), the first guanylate cyclase-C (GC-C) agonist approved in the United States, indicated for irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), and functional constipation in adult and pediatric populations. The underlying technology centers on Ironwood's proprietary GC-C agonist research platform, which targets the intestinal enzyme guanylate cyclase-C found primarily on the intestinal surface, and a separate pipeline asset, apraglutide (a next-generation GLP-2 analog in Phase 3 development for short bowel syndrome with intestinal failure, or SBS-IF), acquired through the 2023 purchase of VectivBio Holding AG.

The company's revenue model is anchored in its U.S. co-development and co-commercialization partnership with AbbVie for LINZESS, under which net sales are shared between the parties and AbbVie administers distribution, sales, marketing, and patient assistance programs; a secondary stream of licensing and royalty revenue flows through the VectivBio subsidiary's arrangement with Ferring International. End customers include adult and pediatric patients with constipation-related GI disorders (treated via wholesalers and specialty pharmacies) and, prospectively, the ~18,000 adult SBS-IF patients across the U.S., Europe, and Japan who depend on parenteral support. Pricing for LINZESS is undergoing a deliberate reset — list price was cut by approximately 50% effective January 2026 to remove inflationary rebate components and improve net pricing dynamics.

Operationally, Ironwood is a focused single-therapeutic-area company: LINZESS has been prescribed to over 5.5 million patients since its 2012 launch and holds approximately 75% market share in the GC-C agonist space, with FY2025 total revenue of $296M and FY2026 revenue guidance of $450-475M supported by adjusted EBITDA guidance of $300M+. The company is led by CEO Thomas McCourt (CEO since 2021) and a GI-experienced executive team; it currently faces a leadership transition with interim CFO Ron Silver appointed in May 2026 following the departure of Greg Martini, while management and the board are conducting a strategic alternatives review announced in early 2026.

Name

Ironwood Pharmaceuticals

Legal name

Ironwood Pharmaceuticals, Inc.

Website

https://ironwoodpharma.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

251–500 employees

Short description

Ironwood Pharmaceuticals is a GI-focused biopharmaceutical company (NASDAQ: IRWD) that discovers, develops, and commercializes treatments for gastrointestinal diseases, headlined by the blockbuster LINZESS co-commercialized with AbbVie and the investigational GLP-2 analog apraglutide for short bowel syndrome.

Ownership category

akta.pro rank

Product category

Gastrointestinal Pharmaceuticals

akta.pro primary industry

General Gastroenterology (HLAKAEAA)

akta.pro secondary industries

Pancreaticobiliary Disorders (HLAKAEAG), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)

Keywords

• Gastrointestinal pharmaceuticals
• Prescription drug development
• Guanylate cyclase agonists
• Specialty biotech therapeutics
• Rare disease treatments

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure, Supply Chain

Revenue model

1. LINZESS (linaclotide) U.S. Net Sales: Ironwood co-develops and co-commercializes LINZESS with AbbVie in the United States. The drug is indicated for irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), and functional constipation across pediatric and adult patient populations. Revenue is generated through product sales to wholesalers and specialty pharmacies with net sales shared between Ironwood and AbbVie.
2. Licensing and Royalty Revenue: Through subsidiary VectivBio AG, Ironwood maintains licensing arrangements including royalty terms with Ferring International Center S.A. (high single-digit percentage for seven years followed by low single-digit percentage on licensed product net sales per the December 2025 settlement amendment).

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Ironwood Pharmaceuticals discovers, develops, and commercializes prescription drugs for gastrointestinal (GI) diseases. Its primary commercial product is LINZESS (linaclotide), an FDA-approved guanylate cyclase-C (GC-C) agonist indicated for irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), and functional constipation across adult and pediatric populations, co-commercialized with AbbVie in the United States. The pipeline includes apraglutide, an investigational once-weekly GLP-2 analog in Phase 3 development for Short Bowel Syndrome with intestinal failure (SBS-IF).

Product overview

Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company with two main products: LINZESS (linaclotide), an FDA-approved GC-C agonist prescription drug for IBS-C, CIC, and functional constipation that is co-commercialized with AbbVie in the U.S., and apraglutide, an investigational once-weekly GLP-2 analog acquired via the VectivBio acquisition in 2023 and currently in Phase 3 development for Short Bowel Syndrome with intestinal failure. The company focuses exclusively on GI diseases and rare conditions, with LINZESS being the blockbuster commercial product and apraglutide representing the key pipeline asset.

Differentiator

Problem solved

Functional benefit

Brands

• LINZESS: Prescription medication (linaclotide) for irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), and functional constipation in adults and pediatric patients 2 years and older
• Apraglutide

Products and services

• LINZESS (linaclotide) FDA-approved prescription medication (orally available peptide GC-C agonist) for the treatment of irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), and functional constipation across adult and pediatric populations (ages 2 and older). Co-developed and co-commercialized with AbbVie in the United States; distributed through wholesalers and specialty pharmacies.
• Apraglutide Investigational next-generation, long-acting, synthetic GLP-2 analog being evaluated as a once-weekly subcutaneous treatment for patients with Short Bowel Syndrome with intestinal failure (SBS-IF). Has successfully completed Phase 2 studies and is currently in Phase 3 development.

Quantifiable outcome

• 97% year-over-year LINZESS U.S. net sales growth in Q1 2026 to $273 million
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Ferring International Center S.A.minorStrategic or Co-development Partner · 18 December 2025Ironwood subsidiary VectivBio AG amended its exclusive license agreement with Ferring International Center S.A. to resolve pending litigation in the U.S. District Court for the Eastern District of Texas. VectivBio will pay Ferring $12.5 million in two installments, along with royalty terms of high single-digit percentage for seven years followed by low single-digit percentage on licensed product net sales. The settlement clarifies intellectual property ownership.
• VectivBio Holding AGcoreStrategic or Co-development Partner · 21 May 2023Ironwood acquired VectivBio Holding AG (a Swiss clinical-stage biotechnology company) through a $1 billion cash tender offer in May 2023. The acquisition expanded Ironwood's pipeline to include apraglutide, an investigational GLP-2 analog being evaluated for short bowel syndrome with intestinal failure (SBS-IF). The deal was completed in H2 2023.
• AbbVie Inc.coreChannel Partner/ Reseller/ DistributorIronwood and AbbVie co-develop and co-commercialize LINZESS (linaclotide) in the United States for irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), and functional constipation across pediatric and adult patient populations. The partnership involves shared development costs, marketing, sales infrastructure, and net sales distribution between the parties.
• International Foundation for Gastrointestinal Disorders (IFFGD)minorStrategic or Co-development PartnerIn 2021, Ironwood sponsored a workshop with IFFGD focused on improving communication between physicians and patients living with GI disease.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Eli Lilly: Large pharmaceutical incumbent with growing exposure to gastrointestinal indications (e.g., incretin-based therapies for obesity/diabetes with GI mechanisms). Comparable as a deep-pocketed incumbent whose strategic moves in adjacent metabolic/GI areas could shape the competitive landscape.
• Pfizer: Global pharmaceutical incumbent with legacy gastroenterology assets and broad primary care commercial infrastructure. Comparable as a large pharma with overlapping primary care and GI capabilities that could compete in or acquire GI specialty assets.
• Takeda Pharmaceutical: Global pharmaceutical company with significant gastroenterology franchise including ENTYVIO for IBD and a history of GI development leadership (former employer of Ironwood's CMO). Comparable as a large incumbent with overlapping GI commercial infrastructure.
• Ferring Pharmaceuticals: Specialty pharma with leading position in reproductive health, urology, and gastroenterology (including SBS-IF via REBYOTA). Comparable as a specialty GI-focused incumbent and apraglutide-related licensing partner through the December 2025 VectivBio settlement.
• Bausch Health (Salix): Houses the Salix gastrointestinal franchise (including TRULANCE through Synergy) and has broad primary care GI infrastructure. Comparable as a competing GI-focused commercial platform with overlapping prescriber relationships.

Direct peers

• Zealand Pharma: Danish biotech developing glepaglutide, a long-acting GLP-2 analog for Short Bowel Syndrome—a direct competitor to Ironwood's apraglutide in the same rare disease indication with similar once-weekly dosing profile.
• AbbVie: Co-commercialization partner for LINZESS in the U.S. and a major gastroenterology player (e.g., HUMIRA, SKYRIZI, RINVOQ in IBD). Directly comparable as a GI-focused commercial-stage pharmaceutical company and Ironwood's most important strategic partner.
• Ardelyx: Specialty GI-focused biopharma commercializing IBSRELA (tenapanor) for IBS-C and XPHOZAH for hyperphosphatemia. Directly comparable as a smaller GI-focused company targeting overlapping patient populations with LINZESS in IBS-C.
• Synergy Pharmaceuticals (Bausch Health): Markets TRULANCE (plecanatide), a GC-C agonist directly competing with LINZESS in chronic idiopathic constipation and IBS-C. Closest direct therapeutic competitor with a similar mechanism of action and overlapping prescriber base.

Others

• Nestlé Health Science: Nutrition-focused health sciences subsidiary of Nestlé with offerings in GI and SBS-IF nutritional support (e.g., parenteral nutrition products). Comparable as an adjacent ecosystem participant in the SBS-IF care continuum that interacts with the same patient population targeted by apraglutide.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ironwoodpharma
• LinkedInlinkedin.com/company/ironwood-pharmaceuticals
• Facebookfacebook.com/368742829931197

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries2 records

Funding overview

Funding rounds10 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ironwood Pharmaceuticals